New biomarkers as putative predictors of breast cancer progression

MARIANELA SCIACCA,; MARÍA DEL PILAR CARBALLO,; EZEQUIEL LACUNZA ; LINA MARINO, ; MARÍA FERNANDA ROCA, ; MARTIN ABBA ; ÉRICA ROJAS BILBAO,; ANA MARIA EIJAN; CATALINA LODILLINSKY

MAR DEL PLATA

Congreso; Reunion Anual de Sociedades de Biociencias SAIC-SAI-SAFIS; 2022

Ductal carcinoma in situ (DCIS) in breast cancer is defined as a proliferation of epithelial neoplastic cells contained within the lumen of mammary ducts (Cowell, 2013). Currently, evidence suggests that in situ tumors are precursors of invasive tumors, but progression markers are not yet available.We have previously demonstrated using intraductal xenograft model that membrane-type 1 matrix metalloproteinase (MT1-MMP) is essential for the transition from in situ to invasive tumors (Lodillinsky, 2016; 2021). Subsequently, we have completed RNAseq analysis(Illumina HISeqTM, p